4-(4-isopropylphenyl)benzoic acid | 5728-35-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4-isopropylphenyl)benzoic acid
• 英文别名: 4'-Isopropyl-biphenyl-4-carbonsaeure；4-Isopropyl-biphenyl-4'-carbonsaeure；4'-Isopropyl-[1,1'-biphenyl]-4-carboxylic acid；4-(4-propan-2-ylphenyl)benzoic acid
• CAS: 5728-35-8
• 化学式: C₁₆H₁₆O₂
• 分子量: 240.302
• InChiKey: HOTQBHJGVGQWFS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(4-isopropylphenyl)benzoic acid 生成 4-Amino-4'-isopropyl-biphenyl
  参考文献：
  名称：

  一些取代的联苯-4-羧酸，4-联苯基乙酸和4-氨基联苯的合成

  摘要：

  描述了一系列取代的联苯-4-羧酸和4-氨基联苯的合成。包括母体联苯-4-羧酸，4-联苯基乙酸和三种取代的4-联苯基乙酸的制剂。

  DOI：

  10.1039/j39660000840
• 作为产物：
  描述：

  4-异丙基苯基硼酸 在 bis[1,2-bis(diphenylphosphino)ethane]palladium lithium hydroxide 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 98.0h， 生成 4-(4-isopropylphenyl)benzoic acid
  参考文献：
  名称：

  Ring-Opening Reaction of Cyclopropanated [60]Fullerenes:  Unexpected Transformation of Methano[60]fullerenes Having an Electron-Donating Group on the Methano-Bridge Carbon

  摘要：

  A series of novel transformations of [60] fullerene derivatives were found, starting from methano[60] fullerenes with an electron-donating group on the methano-bridge carbon. Aminomethano[60]fullerenes, in situ generated by the treatment of their trifluoromethanesulfonic acid salts with a base, were readily converted into 1-acyl-1,2-dihydro[60] fullerenes via the ring opening of the cyclopropane moiety. The aldehyde/ ketones thus obtained were easily hydrolyzed to give 1,2-dihydro[60] fullerene in the presence of hydroxide anions.

  DOI：

  10.1021/ol0705705

文献信息

• ANTI-HEPATITIS C ACTIVITY OF MESO-TETRAKIS-PORPHYRIN ANALOGUES
  申请人：HAMILTON Andrew

  公开号：US20110064694A1

  公开（公告）日：2011-03-17

  The present invention relates to porphyrin analogues, their use in pharmaceutical compositions alone, or combination with other agents and in the treatment and/or prophylaxis of flaviviridae viral infections, especially hepatitis C viral infection, and secondary disease states and/or conditions associated with same.

  本发明涉及卟啉类似物，它们在药物组合物中的使用，或与其他药剂联合使用，并用于治疗和/或预防黄病毒科病毒感染，特别是丙型肝炎病毒感染，以及与其相关的继发性疾病状态和/或条件。
• 4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors
  申请人：Ennis Michael Dalton

  公开号：US20080194590A1

  公开（公告）日：2008-08-14

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) wherein A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , X 4 , X 6 , X 2k , R 2l , R 4 , R 5 , and R 6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明揭示了化合物及其药用可接受盐，其中该化合物具有公式（I）的结构，其中A1，A2，A3，A4，A5，A6，A7，A8，X4，X6，X2k，R2l，R4，R5和R6如本发明详细描述中所定义。还揭示了相应的药物组合物、治疗方法、合成方法和中间体。
• 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors
  申请人：Ennis Michael Dalton

  公开号：US20080200475A1

  公开（公告）日：2008-08-21

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: (I) wherein A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , X 4 , X 6 , R 2a , R x , R 4 , R 5 , and R 6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明公开了化合物及其医药上可接受的盐，其中所述化合物具有以下结构式I：(I)，其中A1，A2，A3，A4，A5，A6，A7，A8，X4，X6，R2a，Rx，R4，R5和R6如发明详细说明中所定义。本发明还公开了相应的制药组合物、治疗方法、合成方法和中间体。
• 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors
  申请人：Ennis Michael Dalton

  公开号：US20080176857A1

  公开（公告）日：2008-07-24

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , X 4 , X 6 , R 2 , R 4 , R 5 , and R 6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明揭示了化合物及其药物可接受的盐，其中化合物具有公式I的结构：其中A1、A2、A3、A4、A5、A6、A7、A8、X4、X6、R2、R4、R5和R6如本发明详细描述中所定义。本发明还揭示了相应的药物组合物、治疗方法、合成方法和中间体。
• DE2535046
  申请人：——

  公开号：——

  公开（公告）日：——